These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31313376)

  • 1. Controlling false discovery proportion in identification of drug-related adverse events from multiple system organ classes.
    Tan X; Liu GF; Zeng D; Wang W; Diao G; Heyse JF; Ibrahim JG
    Stat Med; 2019 Sep; 38(22):4378-4389. PubMed ID: 31313376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hierarchical testing approach for detecting safety signals in clinical trials.
    Tan X; Chen BE; Sun J; Patel T; Ibrahim JG
    Stat Med; 2020 May; 39(10):1541-1557. PubMed ID: 32050050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flagging clinical adverse experiences: reducing false discoveries without materially compromising power for detecting true signals.
    Mehrotra DV; Adewale AJ
    Stat Med; 2012 Aug; 31(18):1918-30. PubMed ID: 22415725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of two multivariate permutation methods for controlling the false discovery proportion.
    Korn EL; Li MC; McShane LM; Simon R
    Stat Med; 2007 Oct; 26(24):4428-40. PubMed ID: 17357994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exact Integral Formulas for False Discovery Rate and the Variance of False Discovery Proportion.
    Sadygov RG; Zhu JX; Deberneh HM
    J Proteome Res; 2024 Jun; 23(6):2298-2305. PubMed ID: 38809146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing safety at the end of clinical trials using system organ classes: A case and comparative study.
    Carragher R; Robertson C
    Pharm Stat; 2021 Nov; 20(6):1278-1287. PubMed ID: 34169636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competition-based control of the false discovery proportion.
    Luo D; Ebadi A; Emery K; He Y; Noble WS; Keich U
    Biometrics; 2023 Dec; 79(4):3472-3484. PubMed ID: 36652258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting potential safety issues in large clinical or observational trials by Bayesian screening when event counts arise from poisson distributions.
    Gould AL
    J Biopharm Stat; 2013; 23(4):829-47. PubMed ID: 23786257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of statistical methods for safety signal detection: a simulation study.
    Chen M; Zhu L; Chiruvolu P; Jiang Q
    Pharm Stat; 2015; 14(1):11-9. PubMed ID: 25329607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the false discovery rate for evaluating clinical safety data.
    Mehrotra DV; Heyse JF
    Stat Methods Med Res; 2004 Jun; 13(3):227-38. PubMed ID: 15198488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian approach for clinical trial safety data using an Ising prior.
    McEvoy BW; Nandy RR; Tiwari RC
    Biometrics; 2013 Sep; 69(3):661-72. PubMed ID: 23845253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing jumps via false discovery rate control.
    Yen YM
    PLoS One; 2013; 8(4):e58365. PubMed ID: 23573190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-sampling strategy to improve the estimation of number of null hypotheses in FDR control under strong correlation structures.
    Lu X; Perkins DL
    BMC Bioinformatics; 2007 May; 8():157. PubMed ID: 17509157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials.
    Mahr A; Golmard C; Pham E; Iordache L; Deville L; Faure P
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):731-741. PubMed ID: 28176407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient methods for signal detection from correlated adverse events in clinical trials.
    Diao G; Liu GF; Zeng D; Wang W; Tan X; Heyse JF; Ibrahim JG
    Biometrics; 2019 Sep; 75(3):1000-1008. PubMed ID: 30690717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graphical approaches for the control of generalized error rates.
    Robertson DS; Wason JMS; Bretz F
    Stat Med; 2020 Oct; 39(23):3135-3155. PubMed ID: 32557848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of false discovery proportion under general dependence.
    Pawitan Y; Calza S; Ploner A
    Bioinformatics; 2006 Dec; 22(24):3025-31. PubMed ID: 17046978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian hierarchical methods in the detection of potentially teratogenic first-trimester medications.
    Cavadino A; Prieto-Merino D; Morris JK
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):337-346. PubMed ID: 31908100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.